Abstract
Prion infections of the central nervous system (CNS) are characterized by a reactive gliosis and the subsequent degeneration of neuronal tissue. The activation of glial cells, which precedes neuronal death, is likely to be initially caused by the deposition of misfolded, in part proteinase K-resistant, isoforms (termed PrPTSE) of the normal cellular prion protein (PrPc) in the brain. Proinflammatory cytokines and chemokines released by PrPTSE-activated glial cells and stressed neurons may contribute directly or indirectly to the disease development by enhancement and generalization of the gliosis and via cytotoxicity for neurons. Recent studies have illustrated that interfering with inflammatory responses may represent a therapeutic approach to slow down the course of disease development. Hence, a better understanding of driving factors in neuroinflammation may well contribute to the development of improved strategies for treatment of prion diseases.
CNS & Neurological Disorders - Drug Targets
Title: Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention
Volume: 8 Issue: 5
Author(s): Constanze Riemer, Sandra Gultner, Ines Heise, Nikola Holtkamp and Michael Baier
Affiliation:
Abstract: Prion infections of the central nervous system (CNS) are characterized by a reactive gliosis and the subsequent degeneration of neuronal tissue. The activation of glial cells, which precedes neuronal death, is likely to be initially caused by the deposition of misfolded, in part proteinase K-resistant, isoforms (termed PrPTSE) of the normal cellular prion protein (PrPc) in the brain. Proinflammatory cytokines and chemokines released by PrPTSE-activated glial cells and stressed neurons may contribute directly or indirectly to the disease development by enhancement and generalization of the gliosis and via cytotoxicity for neurons. Recent studies have illustrated that interfering with inflammatory responses may represent a therapeutic approach to slow down the course of disease development. Hence, a better understanding of driving factors in neuroinflammation may well contribute to the development of improved strategies for treatment of prion diseases.
Export Options
About this article
Cite this article as:
Riemer Constanze, Gultner Sandra, Heise Ines, Holtkamp Nikola and Baier Michael, Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789542014
DOI https://dx.doi.org/10.2174/187152709789542014 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sudden Infant Death Following Hexavalent Vaccination: A Neuropathologic Study
Current Medicinal Chemistry Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Sudden Infant Death Syndrome: A Review of the Literature
Current Pediatric Reviews ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches
Current Drug Targets Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application
Current Drug Targets Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Vascular Patency: A Biomarker and Clinical Target Quantified with High Resolution MRI and Novel Cellular Pathways
Current Neurovascular Research Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Oxidative Medicine in Brain Injury
Current Pharmaceutical Design Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology